The GLP-1 weight-loss and diabetes drug market has hit a stabilization phase, with growth plateauing after an initial surge driven by generic semaglutide launches, according to Pharmatrack’s latest data. Innovator brands from Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Mounjaro) retain leadership despite a slight slowdown in momentum.
Market Dynamics: Generics vs. Innovator Drugs
Pharmatrack’s June report reveals the GLP-1 market now stands at ₹2,055 crore annually, with Lilly’s Mounjaro alone contributing ₹1,300 crore. Semaglutide brands (Wegovy, Ozempic, and generics) accounted for ₹649 crore in the same period. Key insights include:
- Innovator brands (Wegovy, Ozempic, Poviztra, Extensior) captured 40% of value sales but only 18% of unit sales in June.
- 31 generic semaglutide brands, from firms like Sun Pharma and Dr. Reddy’s, dominated 82% of unit sales after patent expiry in March 2026.
- Other GLP-1 drugs like Dulaglutide (₹67 crore) and Liraglutide (₹37 crore) show niche but steady demand.
Investor Implications: Loyalty vs. Cost Sensitivity
While generics expanded market access, their rapid adoption has now "optimally covered" demand, per Pharmatrack’s Sheetal Sapale. Innovator drugs, however, continue month-on-month growth, signaling a loyal prescriber base. Tirzepatide (Lilly’s Mounjaro) recovered post-generics launch, aligning with pre-surge sales levels.
Analysts note this stabilization reflects a maturity phase, where cost-sensitive patients have shifted to generics, but premium segments remain resilient. Lilly’s tie-up with Cipla for a second Mounjaro brand further secures its position.
Future Outlook: Incremental Growth Ahead
With the initial demand spike subsiding, Pharmatrack expects incremental monthly sales going forward. The plateau suggests the market has absorbed most price-sensitive users, while innovators leverage brand equity and clinical trust. For investors, this signals a shift from explosive growth to sustainable, steady returns in the GLP-1 segment.
